Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - anti inhibitor coagulant complex - injection, powder, for solution - 50 u/ml - anti inhibitor coagulant complex 50 u/ml

Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - anti inhibitor coagulant complex - injection, powder, for solution - 25 u/ml - anti inhibitor coagulant complex 25 u/ml

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - anti-inhibitor coagulant complex (unii: cs849dun3m) (anti-inhibitor coagulant complex - unii:cs849dun3m) - anti-inhibitor coagulant complex 500 [usp'u] in 20 ml - feiba is an anti-inhibitor coagulant complex indicated for use in hemophilia a and b patients with inhibitors for: - control and prevention of bleeding episodes - perioperative management - routine prophylaxis to prevent or reduce the frequency of bleeding episodes. feiba is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor viii or coagulation factor ix. - known anaphylactic or severe hypersensitivity reactions to feiba or any of its components, including factors of the kinin generating system. - disseminated intravascular coagulation (dic). - acute thrombosis or embolism (including myocardial infarction). risk summary there are no data with feiba use in pregnant women to inform a drug-associated risk. there are no adequate and well-controlled studies in pregnant women. animal reproduction studies have not been conducted with feiba. it is also not known whether feiba can cause fetal harm when administered to a

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - feiba - pdr+solv for soln for inf - 500

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - feiba - pdr+solv for soln for inf - 1000

Malta - English - Medicines Authority

baxalta innovations gmbh industriestrasse 67, 1221, vienna, austria - powder and solvent for solution for infusion - factor viii inhibitor bypassing fraction 100 u/ml - antihemorrhagics

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - factor viii inhibitor bypassing fraction -

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

1 kit (1 glass vial of 1000 u feiba (powder) + 1 glass vial of 20 ml sterilised wfi + 1 baxject ii hi-flow + 1 disposable syringe 20 ml + 1 butterfly needle + 1 disposable needle) -

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

modern pharmaceutical company austria - 1 kit (1 glass vial of 1000 u feiba (powder) + 1 glass vial of 20 ml sterilised wfi + 1 baxject ii hi-flow + 1 disposable syringe 20 ml + 1 butterfly needle + 1 disposable needle) - injection - 50u/ml - cardiovascular system-antifibrinolytics , haemostatics

Israel - English - Ministry of Health

takeda israel ltd - factor viii inhibitor bypassing fraction - powder and solvent for solution for injection/infusion - factor viii inhibitor bypassing fraction 1000 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors .control of bleeding in hemophilia b patients with inhibitors, if no other specific treatment is available.